the just That's how you, CFO at time Thank to I'd important am the in assuming and company's be by this I hello pleased Rich everyone. off role like kick of to evolution. saying great.
from and on profitability potential strategic optimistic drive about achieving announced of these targets. priorities XXXX, XXXX. company's meaningful value creation, I'm our value-enhancement are our plan perspective that initiatives. the in financial includes As the and we paramount commitment the The income long-term focus of in we established At to a and XX% of approximately total approximately net end company XXXX to Efficient revenues plan a through XX% clear. the for non-GAAP operational are business of value management a
pipeline growth portfolio of that within next will driven we the commercial to the growth seek infrastructure major and few we the proprietary as advance products operating drives by the the R&D in our commercial we and the and replenish our diverse optimize and products on parallel that investments overall in our expect also Over to focus of years, cost be our will model. spend of our topline efforts continued levers business managing
efforts Turning by to results caused financial to with which our pleased our COVID-XX business efficient focus underscore reflect growth. our driving I'm of significant pandemic. commitment XXXX our our the performance, in bottom-line on to management execution disruptions response and the These demonstrate
GAAP VIVITROL the total royalty our driven loss the For we billion, a the of a the $XXX.X revenue resilience stabilization strength half the net and of income million. in portfolio second revenues. From of $X.XX of by recorded non-GAAP million manufacturing of of net we diverse and year, generated perspective, of year, and ARISTADA, $XX.X bottom-line a and
it's our million of XXXX $XXX results important to purposes revenue year-over-year, to included the VUMERITY. comparison remember the related of of approval that For
income you If XXXX, our than exclude this milestone commitment again by million actually from to which improved year-over-year, demonstrates net revenue $XXX driving non-GAAP more bottom-line growth.
lower $XX year, adjustments in This in part of XX.X% favorable despite sales pandemic QX a then by units full the time. this net we minimal gross-to-net the approximately due offset QX. million offset VIVITROL impacted for quarter Medicaid fourth adjustments which the XXXX. which was Gross-to-net recent from decreased VIVITROL reserves inventory decreased but of we an restrictions year. in sequentially to the million. increased was of improved our over in QX XX.X% Fourth to year-over-year. units VIVITROL And $XX from years, was departure at the sales to adversely the year-end to XX.X% than by were of by million $XXX.X the from For trends in build XX.X% and year the million. X% were increasing pandemic-related quarter net course in net in $X.X flat population, saw favorable adjustments increased X% approximately the by US sales sales during recorded
ARISTADA to family. Turning the product
Medicaid For year, year by to year-over-year to volume sales XX% adjustments net primarily were to increased growth. XX% XXXX Gross-to-net utilization. the for ARISTADA in XX.X% million, $XXX XX% the due compared increased driven
XX% levels net was by $XX.X $X.X we of and during worked Gross-to-net expect quarter expected XXXX. million. XX% be quarter fourth greater will fourth first somewhat sales build year-over-year inventory and This the quarter, increased adjustments sequentially down increased in For the than the approximately of inventory increased and to XX.X% the million. of to XXXX course
our on business. Moving manufacturing to and royalty
INVEGA For in the and was SUSTENNA, million revenues the This from recorded $XXX.X well as royalty by $XX.X which compared year. year, manufacturing we revenues $XXX contributed to as year. VUMERITY, of million from in growth driven continued primarily prior million, increase the
prior to million expenses year. nearly expenses year-over-year. in of for XXXX terms the in compared $XXX.X operating our were R&D by $XXX.X In same period decreased the $XXX expenses for million XXXX total million,
Now potential R&D our to R&D see that in where quarter of highest return. And the to the this related million Rodin programs decrease charge we our reflects million. expenses in focus also of fourth expenses in XXXX of efforts acquisition measures the the XXXX, management the the included a investment COVID in XXXX expense $XXX.X for and year. ongoing decreased restructuring year $XXX.X impact XXXX to from of SG&A $XX.X XXXX, during reflecting million of
total release to fully $XXX the approximately by balance position The $XXX of XXXX approximately partially and start which company's capital $XXX issued expectations from of by a outstanding expenditure of changes, the year, ended are non-GAAP of the to we up cash year, income I'll capital cash primarily debt earlier was shift million at We net end $XX with our total Turning million. million press financial in year. million this driven $XXX investments, in sheet. the at morning. the in XXXX, for the million approximately our working in net outlined resulting now and offset
conditions These ability pandemic-related account clinical could also our conditions of to the investments program not our portfolio. reflect development LYBALVI expectations expectations strategic launch for be assume potential commercial negatively meet partnerships the in nemvaleukin. improvement sort nemvaleukin expectations anticipated, advance improve to any or anticipated other half note, not an impacted. and of second If Of as opportunities do growth our for portfolio anticipated Our XXXX. the do these of focused both of the for across and expectations
billion with billion. to range of mind, the we for revenues topline that in So to expect in be $X.X $X.XX total the
increased Medicaid sales we adjustments For of the XX%, to utilization. $XXX driven approximately net in by range and $XXX million gross-to-net million of expect VIVITROL
second -- quarter. range again to with reflecting expect demand despite adjustments and ARISTADA be approximately the for our we sales Medicaid XX%, will expect the million me, $XX proprietary sales $XX excuse sales that utilization. expect due VIVITROL, million, to first expect underlying products, in by historical growth down offset For anticipated is we million both of line approximately patterns, net lower to approximately increase to in slightly the ARISTADA, to product It with $XXX increased volume sequentially, we to XXXX resume million seasonal growth, sequential quarter $XX expected to to net to which gross-to-net $XXX growth do million for for we net numbers. million important in ARISTADA however note $XX for In
$XX for of And we now second to ahead ranges I'll range look total provide in the products. portfolio, rather out of half sales anticipated plan XXXX up guidance of approved, revenues our in if note just launch a we net that to a the proprietary we than by specific total next modest in contribution a transition include as Our expansion year. in our year net broken as product may LYBALVI, of expectations sales to for million the of
of to terms range to a expenses $XXX to to from goods inhibitor be IND HDAC in for million. range to first includes to is of $XXX expected $XX it with to are range platform. volumes R&D increase important of the emerge that, candidate sold a or this equivalent cost ALKS $XXX million $XXX operating payment, to clinical submission XXXX, million expected And milestone an million million. In of for is note expenses related of potential XXXX, the our the our
LYBALVI. are in as Our cycle million, for advance the expected development expected this million in well expenses to to of to investment staged investment to XXXX LYBALVI. $XXX year-over-year R&D the range million. $XX of the And anticipated $XX we in life net expect in $XXX GAAP personnel loss expense range sales to also $XXX million. our and income to range continued increased nemvaleukin, studies support expect be program, we net in $XXX non-GAAP million of investment as we launch management in increase reflects marketing as million be and of for the be the Overall, reflects range SG&A
ways financial The designed committed to set trajectory, we're drive number will from in are the efficiencies XXXX, Now, to the value-enhancement for are operating revenue achieve however, our to XXXX as to making are while of from the to costs a and launch a foundation business, the in for And we achieving maintaining our XXXX. manage trajectory on achieved targets targets. profitability, driving them. investments we achieve In our plan LYBALVI. plan. psychiatry lay focus perspective, we of forth profitability the there in Irrespective we leverage non-GAAP growth, establish we
So, on our well to positioned execute strategic in conclusion, we XXXX entered priorities.
to launch Our commercial diverse and sharing of our with look that, Todd hand for review our nemvaleukin on to I commercial of program, the the the updates portfolio, call a and I'll And long-term landscape. distinct this our forward anticipated LYBALVI provide advancement year to value creation, foundation over progress.
